The new infusion for maple syrup urine disease is for patients who cannot have an oral or enteral branched-chain amino ...

Fatty liver disease affects millions of people worldwide, with nonalcoholic fatty liver disease (NAFLD) being the most common ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous ...

She is the unusual individual who has escaped all the common age-related diseases, defying what most of us expect from the ...

Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis ...

This accounted for the leg edema, the treating of which was straightforward ... She is the unusual individual who has escaped all the common age-related diseases, defying what most of us expect from ...

Bayer A.G.'s stock is undervalued but faces risks with declining profits & regulatory pressures. Click for my updated look at ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

Hoburg and Brunstetter will take center stage, offering attendees the rare opportunity to hear firsthand their clinical ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...